CSPG4 and metastatic melanoma: For instance, the anti-idiotypic mAb MK2-23, which mimic the epitope recognized by anti-CSPG4 mAb 763.74, induced specific antibody responses in metastatic melanoma patients that correlated with prolonged survival and reduced metastatic spread [189].